Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Roundup – 7 March 2019

Executive Summary

Biocon believes its new biologics chief in India will lead the firm to become a “major global player”, Glenmark names Riva to lead its recently spun-off innovation business, and Recipharm bolsters its management team by adding Chouhan to lead sales activity in North America.

You may also be interested in...



Góra Leads Neuraxpharm’s Push Into Poland

Neuraxpharm has kicked off its operations in Poland with the appointment of Wojciech Góra as general manager of its new Neuraxpharm Polska business.

Glenmark Plans To Spin Out A US-Based ‘Innovation’ Business – And May Pull The Plug On Advair

Having amassed a significant pipeline of innovative assets, India’s Glenmark has made the choice to spin them off into a new company that will be housed in the US. 

Alvogen Settles With Celgene Over US Revlimid

Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel